Tyrosine Kinase Inhibitors (TKIs) in Cancer Targeted Therapy (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 169
Special Issue Editor
Interests: molecular-targeted therapies in cancer; oncogenic signaling pathways; prognostic biomarkers; cancer metabolism; molecular mechanisms of therapy resistance in oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of "Tyrosine Kinase Inhibitors (TKIs) in Cancer Targeted Therapy" (https://www.mdpi.com/journal/cancers/special_issues/TKI_Cancer_Therapy).
An ideal anticancer strategy would be one that selectively restricts the proliferation and survival of tumor cells while sparing normal cells. Molecular-targeted therapies, which are tailored to interfere specifically with the key molecular aberrations that drive the malignant phenotype, are designed to meet this criterion, holding great promise for expanding the therapeutic window in cancer cases. The definition of signaling pathways to understand tumor biology, combined with the rapid development of technologies that allow for high-throughput molecular analysis of tumors, has led to a new era of precision medicine in oncology, with the development of drugs targeted against oncogenic tyrosine kinases. A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases, which are enzymes responsible for the activation of many proteins via signal transduction cascades.
Although the concept of oncogene addiction has led to some initially impressive clinical results, it is also apparent that tumors can often escape their oncogene addicted state, causing relapse of the tumor even after pronounced initial responses. Thus, the main challenges in precision oncology include both the identification of tyrosine kinases that enable for the selection of patient populations that are most likely to benefit from the treatment and anticipation of the driven resistance molecular mechanisms.
This Special Issue will highlight the importance of tyrosine kinase-targeted therapies in oncological patient management, covering new basic and preclinical discoveries in the fields of predictive biomarkers or resistance drivers to TKI in cancer patients.
Dr. Olga Martinho
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- molecular-targeted therapies
- TKI inhibitors
- oncogene signaling pathways
- precision oncology
- predictive biomarkers
- therapy resistance
